This compound is a pharmaceutical intermediate specifically used in the manufacturing of impurities related to Afatinib. It features a complex organic structure containing multiple aromatic rings and amide functional groups, indicating a high molecular weight and potential for use in specialized chemical synthesis.
Portée du contenu: Les informations de cette page concernent l'identification chimique ainsi que les contextes d'approvisionnement industriel, de recherche et de production. Elles ne constituent ni une allégation thérapeutique, ni un avis médical, ni une notice d'utilisation médicamenteuse.
Approvisionnement ou fourniture de ce composé?
Publiez votre inventaire ou une demande d'achat
CAS 2223677-65-2
(S)-N1-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-((TETRAHYDROFURAN-3-YL)OXY)QUINAZOLIN-6-YL)-N2,N2-DIMETHYLOXALAMIDE
pharmaceutical intermediate
(S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)but-2-enamide (Afatinib Impurity)
n.a
(S)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)formamide (Afatinib Impurity)
research impurity reference standard
Diethyl P-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]amino]-2-oxoethyl]phosphonate
Active pharmaceutical ingredient
(S,E)-2-((3-Chloro-4-fluorophenyl)(6-(4-(dimethylamino)but-2-enamido)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-4-yl)amino)malonic acid
Pharmaceutical intermediate for Afatinib impurities
(S)-4-Methyloxazolidine-2,5-dione
pharmaceutical intermediate
1-(4-chlorophenyl)-3-oxoisoindoline
Pharmaceutical intermediate synthesis
4-(4-chlorophenyl)-1H-2,3-benzoxazin-1-one
Pharmaceutical intermediate
N,N'-bis[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]oxamide
NMHSIKFQDIYZSG-VXKWHMMOSA-N
C1COC[C@H]1OC2=C(C=C3C(=C2)N=CN=C3NC4=CC(=C(C=C4)F)Cl)NC(=O)C(=O)NC5=C(C=C6C(=C5)C(=NC=N6)NC7=CC(=C(C=C7)F)Cl)O[C@H]8CCOC8
—